Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
about
Lymphadenectomy for the management of endometrial cancerWhat Is the Best Preoperative Imaging for Endometrial Cancer?Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.Role of nuclear progesterone receptor isoforms in uterine pathophysiology.Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas.Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.Implications of a two-step procedure in surgical management of patients with early-stage endometrioid endometrial cancer.DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer.PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort studyEndometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors.An immunohistochemical study on the expression of sex steroid receptors, Ki-67 and cytokeratins 7 and 20 in feline endometrial adenocarcinomas.L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial CarcinomaSparse feature selection for classification and prediction of metastasis in endometrial cancer.ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma.Overexpression of microRNA-205 predicts lymph node metastasis and indicates an unfavorable prognosis in endometrial cancer.HER2-positive endometrial cancer subtype carries poor prognosis.Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.Current status of molecular biomarkers in endometrial cancer.Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer.The clinical management of inoperable endometrial carcinoma.Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences.Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project.Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients.Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction.Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study.Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer.Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients.Contribution of cervical cytology in the diagnostic work-up of patients with endometrial cancer.Lymphadenectomy for the management of endometrial cancer.Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer.Type of vascular invasion in association with progress of endometrial cancer.Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer.
P2860
Q24187095-502A01E4-88A0-4C92-B70D-6FD58DE6F5A8Q28077761-8DAD08B5-E8D1-43CF-B64E-7FCCA82EA01BQ33572253-12309036-559C-4B18-967F-055DE88BCEE7Q34448400-D84A4FD5-EF57-456B-8061-659C3B5FF5FCQ35121869-FC468FFC-25F5-43DA-9A79-3A385242DE47Q35176084-6543DE70-1C14-43B0-9519-E651481C5947Q35419055-960FF031-E9E2-467E-B3C8-0199FD3F8EC8Q35603652-FC72604F-2FB4-4094-A02D-BD74742DB71DQ35678094-056728EB-C111-4289-BB5B-A9FF8951C003Q35739831-7836BBFB-EC95-4ADD-B59D-CCA4D85E8D5DQ35744464-665A74F2-06B5-4C0E-BDA6-AFD0A79F4E7FQ35927619-62DDAAC0-6CAC-4B42-81CC-CF5357D32795Q36329414-11BB654D-2147-4ACF-A461-177971675B1BQ36414073-E3B145F4-29BB-4D3D-AC3A-F35A7F5B8734Q37582086-22E18B66-F06F-4EAD-A51E-0E636F98D762Q37700593-777331B3-22E1-4B6C-83D7-BE4162C77AEAQ37706048-EA0D6AF8-B957-45D2-B3C1-C8E5DD118735Q38234228-5CBE17C8-BB1D-4EDD-B475-4FD66FBA781FQ38648524-C0F571E8-8F54-4191-8A7A-92A28665634AQ38783340-5C8EEABB-4804-4240-AD69-B80CA594C7FBQ38788210-B6CFD103-99DA-4FCC-B4A9-AC0FAAF2B4D8Q39691526-3D910178-6683-4CC1-8350-D25E2DFD972EQ40104862-1F95F608-046C-4C66-A920-E08181600B60Q40396155-6E65B4A9-D0B9-4415-8A3C-C18809166CA6Q41235932-3D5325B6-6283-46DA-9B22-61277F6DEBB2Q42317488-CDCC72C4-35AE-4AC0-964B-8B33B75DF3DEQ46764265-DBAFCF2A-1748-4688-AC96-84656AF1C484Q47146817-1E0BE978-9A66-4F0F-B9C7-E9D9D3E473B2Q47762804-E7AE2560-8501-40BB-A658-9F950DDDA53AQ47884971-287A368B-24E6-4014-9DD8-4BBB4E51BBA4Q48305261-C2F6A3D9-BAF2-468E-BD43-2B2D4FD9F2D2Q49629358-E72B52C4-BE58-4393-87C0-86D139A4A8F4Q50090882-00601745-34E9-4C87-90C1-4BFD1AF84E1F
P2860
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Hormone receptor loss in endom ...... prospective multicentre trial.
@en
Hormone receptor loss in endom ...... prospective multicentre trial.
@nl
type
label
Hormone receptor loss in endom ...... prospective multicentre trial.
@en
Hormone receptor loss in endom ...... prospective multicentre trial.
@nl
prefLabel
Hormone receptor loss in endom ...... prospective multicentre trial.
@en
Hormone receptor loss in endom ...... prospective multicentre trial.
@nl
P2093
P50
P1476
Hormone receptor loss in endom ...... prospective multicentre trial.
@en
P2093
Anne C Staff
Elisabeth Wik
Frederic Amant
Harald Helland
Helga B Salvesen
Henrica M J Werner
Ingrid Vandenput
Ingunn M Stefansson
Janusz Marcickiewicz
MoMaTEC study group
P304
P356
10.1016/J.EJCA.2013.06.016
P577
2013-08-08T00:00:00Z